search

Active clinical trials for "Dyskinesias"

Results 181-190 of 254

Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias...

Idiopathic Parkinson Disease

This is a 41-week trial composed of two consecutive parts (Part A, 14 weeks and optional Part B, 27 weeks) to evaluate the efficacy of levetiracetam in controlling levodopa induced dyskinesias in adults with Idiopathic Parkinson's Disease, without negative impact on the benefit on the motor function of the antiparkinsonian treatment.

Completed10 enrollment criteria

Respiratory Physiotherapy Performed by Simeox In Patients With Primary Ciliary Dyskinesia

Primary Ciliary Dyskinesia

Primary ciliary dyskinesia (PCD) is characterized by impaired airway clearance and mucus stagnation. This results in recurrent upper and lower respiratory tract infections often leading to chronic inflammation and, if not treated early and properly, to irreversible functional and structural changes of the respiratory tract. As there is no causal treatment of PCD yet, airway clearance techniques (ACT) provide fundamental care for these patients. Simeox is a new airway clearance device, recently developed by the French company PhysioAssist. This technology is based on pneumatic vibrations generated by the device itself. Vibrations are induced by rapidly alternating between atmospheric and negative pressure as the patient exhales, providing the most effective clearance of mucus from the lungs. Vibrations of different intensity and frequency are known to alter the rheological properties of mucus in the airways, whilst the negative pressure during exhalation helps to mobilise and drain the mucus to the central bronchi. Although there have not yet been any evidence based papers published clarifying the effect of Simeox specifically in patients with PCD, using up-to-date information, experience, and positive feedback from our patients, we assume that there could be a significant benefit for the effectiveness of ACT.

Completed5 enrollment criteria

Validation of Dyskinesia Rating Scales

Parkinson's Disease

This study will evaluate the responsiveness of a variety of available dyskinesia rating scales to treatment with amantadine or placebo in Parkinson's disease patients with dyskinesia. The study will be a parallel, double-blind, randomized trial of 68 patients treated with amantadine or placebo for 8 weeks. Pre-treatment evaluations will be performed and compared to end of study evaluations on the best treatment dose (200 or 300 mg amantadine or matching placebo) daily. Safety evaluations will be conducted. The responsiveness of the different scales will be evaluated statistically with a mixed model in which changes in the outcome measures over time will include a fixed effect of treatment group assignment. The model will additionally account for random effects of intercepts (the scale scores at baseline) that will include both random variation (person-specific) and specific variation associated with rate of change in outcome. The investigators may include adjustments for possible confounding covariates, including baseline demographics and center. The goal of the program is to provide researchers with the best scale(s) to distinguish dyskinesia change in Parkinson's disease (PD) associated with amantadine in comparison to placebo and to establish the magnitude of effect achievable with amantadine as a comparator "gold standard" that must be met or surpassed by future anti-dyskinetic agents. Additionally, with the use of paper and pencil questionnaires, the study will investigate the impact of patient optimism and patient and rater expectation of positive effects on the dyskinesia rating outcomes.

Completed15 enrollment criteria

Feasibility of Consumption of Nutritional Supplementation in Primary Ciliary Dyskinesia

Primary Ciliary Dyskinesia

Feasibility study to understand and gain preliminary information on tolerability and palatability of an oral nutritional supplement gel in a clinical Primary Ciliary Dyskinesia population. To determine if dietary intake is affected by the consumption of the nutritional supplement. Explore possible future outcome measures that could be important in determining impact of this nutritional intervention on this patient group. Participants will be provided with the gel supplements and alongside will have other standard and non standard care measures assessed lung function (FEV1%) number of exacerbation's during study period vitamin D status Bio impedance analysis (BIA) skin-fold measures (e.g. Tricep Skin-fold (TSF) Mid upper arm circumference (MUAC) Handgrip strength (HGS) quality of life measures 6-minute walking tests. Hypothesis Patients with PCD can successfully consume 2 gel supplements per day for a period of 3 months with no effect on dietary intake.

Completed7 enrollment criteria

Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia

DyskinesiaMedication-induced

An 8-week study to examine safety and efficacy of levetiracetam in patients with neuroleptic-induced tardive dyskinesia

Completed8 enrollment criteria

Scapular Upward Rotation Exercises for Subjects With Deperessed Scapular Alignment

Scapular Dyskinesis

It was hypothesized that: There is no statistical significant effects of a scapular vupward rotation exercise (SURE) on scapular alignment in subjects with scapular downward rotation syndrome (SDRS). There is no statistical significant effects a scapular upward rotation exercise (SURE) on mechanosensitivity of the upper limb peripheral nervous system in a depressed scapular alignment subjects. There is no statistical significant effects a scapular upward rotation exercise (SURE) on pressure Pain Threshold in a depressed scapular alignment subjects. There is no statistical significant effects a scapular upward rotation exercise (SURE)on Strenght Duration Curve measurement in a depressed scapular alignment subjects.

Unknown status15 enrollment criteria

Assessment of the Effects of Mental Practice on Tongue Strength in Brain-damaged Patients

MovementInvoluntary

The main objective is to evaluate the effects of action-observation training on tongue strength in brain-damaged patients.

Unknown status10 enrollment criteria

Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease...

Levodopa Induced Dyskinesia

Levodopa-induced dyskinesias have been associated with irregular oscillatory discharge characteristics of basal ganglia. From the other hand, LEV which shares a different electrophysiologic profile than other antiepileptics, inhibits hyper-synchronization of abnormal neuronal firing in experimental models of epilepsy. LEV also reduces levodopa-induced dyskinesias in MPTP-lesioned macaques and modulates "priming phenomenon" which associated with long-term changes in synaptic function that can lead to dyskinesias in PD. Study objectives : To evaluate the effects of levetiracetam (LEV) in two doses (500 and 1000mg) vs placebo on disabling dyskinesias that develop as result of long-term treatment with levodopa, occurring at the time of maximal clinical improvement in patients with Parkinson's disease (PD). To evaluate the safety of LEV in patients with PD and antiparkinsonian medication.

Unknown status13 enrollment criteria

Clinical Study on Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With...

L-DOPA-Induced Dyskinesia

A randomized, double-blind, placebo-controlled, multi-center clinical trial was conducted to observe the improvement in the level of dyskinesia in patients with Parkinson's disease during the 12-week period of oral treatment with Tianqi Pingchan Granule Combined With Amantadine. To observe the differences of the safety and effectiveness between Tianqi Pingchan Granule combined with amantadine and placebo combined with amantadine.

Unknown status21 enrollment criteria

Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.

Tardive Dyskinesia

The purpose of this study is to explore the therapeutic effect and mechanism of transcranial magnetic stimulation (rTMS) in the treatment of the tardive dyskinesia.

Unknown status10 enrollment criteria
1...181920...26

Need Help? Contact our team!


We'll reach out to this number within 24 hrs